📊 ENSCW Key Takeaways
Is ENSCW a Good Investment? Thesis Analysis
Ensysce Biosciences is a severely distressed pharmaceutical company with minimal revenue ($3.2M), massive operating losses (-$7.5M), and a -232.6% net margin indicating the business is burning cash at an unsustainable rate. With negative free cash flow of -$6.4M and only $1.7M in cash reserves against $2.3M in liabilities, the company faces imminent liquidity constraints and potential insolvency without significant capital infusion or operational turnaround.
Why Buy ENSCW? Key Strengths
- Positive current ratio of 1.27x provides short-term liquidity cushion
- No long-term debt reduces leverage risk and balance sheet complexity
- Cash position of $1.7M provides runway for near-term operations
ENSCW Investment Risks to Consider
- Revenue of $3.2M is insufficient to cover operating expenses of $10.7M, indicating fundamental business model failure
- Negative free cash flow of -$6.4M will deplete $1.7M cash reserve in approximately 3 months at current burn rate
- Operating margin of -234.2% and net margin of -232.6% demonstrate the company is not close to profitability
- Zero insider purchases in last 90 days suggests lack of management confidence in the business
- ROE of -615.6% and ROA of -233.0% indicate severe shareholder value destruction
Key Metrics to Watch
- Monthly cash burn rate and months of cash runway remaining
- Revenue growth trajectory and path to profitability
- Insider buying activity as indicator of management confidence
ENSCW Financial Metrics
💡 AI Analyst Insight
Ensysce Biosciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ENSCW Profitability Ratios
ENSCW vs Healthcare Sector
How Ensysce Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENSCW Overvalued or Undervalued?
Based on fundamental analysis, Ensysce Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENSCW Balance Sheet & Liquidity
ENSCW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Ensysce Biosciences, Inc.'s revenue has grown significantly by 48% over the 5-year period, indicating strong business expansion. The most recent EPS of $-70.40 indicates the company is currently unprofitable.
ENSCW Growth Metrics (YoY)
ENSCW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $493.1K | $661.8K | $1.00 |
| Q2 2025 | $181.8K | -$1.7M | $-0.79 |
| Q1 2025 | $305.7K | -$1.9M | $-1.39 |
| Q3 2024 | $435.4K | $661.8K | $0.07 |
| Q2 2024 | $181.8K | -$2.0M | $-0.22 |
| Q1 2024 | $305.7K | -$2.2M | $-0.55 |
| Q3 2023 | $279.4K | -$2.7M | $-0.87 |
| Q2 2023 | $207.5K | -$2.2M | $-0.98 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENSCW Capital Allocation
ENSCW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Ensysce Biosciences, Inc. (CIK: 0001716947)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENSCW
What is the AI rating for ENSCW?
Ensysce Biosciences, Inc. (ENSCW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENSCW's key strengths?
Claude: Positive current ratio of 1.27x provides short-term liquidity cushion. No long-term debt reduces leverage risk and balance sheet complexity.
What are the risks of investing in ENSCW?
Claude: Revenue of $3.2M is insufficient to cover operating expenses of $10.7M, indicating fundamental business model failure. Negative free cash flow of -$6.4M will deplete $1.7M cash reserve in approximately 3 months at current burn rate.
What is ENSCW's revenue and growth?
Ensysce Biosciences, Inc. reported revenue of $3.2M.
Does ENSCW pay dividends?
Ensysce Biosciences, Inc. does not currently pay dividends.
Where can I find ENSCW SEC filings?
Official SEC filings for Ensysce Biosciences, Inc. (CIK: 0001716947) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENSCW's EPS?
Ensysce Biosciences, Inc. has a diluted EPS of $-3.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENSCW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Ensysce Biosciences, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENSCW stock overvalued or undervalued?
Valuation metrics for ENSCW: ROE of -615.6% (sector avg: 15%), net margin of -232.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENSCW stock in 2026?
Our dual AI analysis gives Ensysce Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENSCW's free cash flow?
Ensysce Biosciences, Inc.'s operating cash flow is $-6.3M, with capital expenditures of $123.6K. FCF margin is -201.1%.
How does ENSCW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -232.6% (avg: 12%), ROE -615.6% (avg: 15%), current ratio 1.27 (avg: 2).